Sharda Cropchem Ltd Valuation Shifts to Fair Amid Strong Market Performance

Valuation Metrics: A Closer Look

As of early February 2026, Sharda Cropchem's price-to-earnings (P/E) ratio stands at 18.45, a figure that has nudged the company’s valuation grade from attractive to fair. This P/E multiple, while higher than its historical lows, remains moderate when juxtaposed with several peers in the pesticides and agrochemicals industry. For instance, Bayer CropScience trades at a steep P/E of 32.96, and Anupam Rasayan commands an even more elevated multiple of 98.64, signalling a very expensive valuation. Conversely, Dhanuka Agritech, with a P/E of 16.4, retains a very attractive valuation status, underscoring the diversity in market perceptions within the sector.

Complementing the P/E ratio, Sharda Cropchem’s price-to-book value (P/BV) is currently 3.90. This figure suggests that the market values the company at nearly four times its book value, a premium that reflects investor confidence in its growth prospects and asset quality. The enterprise value to EBITDA (EV/EBITDA) ratio of 10.83 further supports a fair valuation stance, especially when compared to peers like BASF India, which trades at a higher EV/EBITDA of 26.56 despite being rated attractive, and Rallis India at 14.27.

Financial Performance and Quality Indicators

Sharda Cropchem’s robust financial metrics underpin its valuation. The company boasts a return on capital employed (ROCE) of 24.83% and a return on equity (ROE) of 16.89%, both indicative of efficient capital utilisation and strong profitability. These figures are particularly impressive in the context of the agrochemical industry, where capital intensity and regulatory challenges often weigh on returns.

Moreover, the company’s PEG ratio, a measure that adjusts the P/E ratio for earnings growth, is exceptionally low at 0.14. This suggests that Sharda Cropchem’s earnings growth potential is not fully priced into its current valuation, offering a compelling argument for investors seeking growth at a reasonable price. The dividend yield, while modest at 0.78%, complements the company’s growth orientation, signalling a balanced approach to shareholder returns.

Market Performance: Outpacing Benchmarks

Sharda Cropchem’s stock price has demonstrated remarkable resilience and growth, with a current market price of ₹1,157.00, up 1.21% on the day, and nearing its 52-week high of ₹1,197.00. The stock’s performance over various periods starkly contrasts with the broader market, as represented by the Sensex. Over the past week, the stock surged 17.22%, dwarfing the Sensex’s 0.91% gain. The one-month return of 36.29% is particularly striking against the Sensex’s decline of 2.49% in the same period.

Year-to-date, Sharda Cropchem has appreciated by 32.33%, while the Sensex has fallen 2.24%. Over longer horizons, the company’s outperformance is even more pronounced: a 106.48% return over one year versus the Sensex’s 6.44%, a 140.34% gain over three years compared to the Sensex’s 36.94%, and an extraordinary 298.48% over five years against the Sensex’s 64.22%. The decade-long return of 417.21% further cements Sharda Cropchem’s status as a high-growth stock within its sector.

Comparative Valuation: Contextualising Sharda Cropchem

When analysing Sharda Cropchem’s valuation, it is essential to consider the broader industry landscape. The company’s current P/E of 18.45 places it in a fair valuation bracket, a shift from its previously attractive rating. This change reflects a combination of rising share prices and evolving market expectations. In contrast, peers such as Bharat Rasayan trade at a slightly higher P/E of 21.51 but share a similar fair valuation grade, while companies like Bhagiradha Chemicals, with a P/E exceeding 240, are classified as very expensive.

EV/EBITDA multiples also highlight Sharda Cropchem’s relative value. Its 10.83 multiple is significantly lower than Bayer CropScience’s 26.14 and Anupam Rasayan’s 29.67, suggesting that Sharda Cropchem offers a more reasonable entry point for investors seeking exposure to the agrochemical sector without overpaying. The PEG ratio further accentuates this point, with Sharda Cropchem’s 0.14 indicating undervalued growth potential compared to Bayer’s 6.52 and Dhanuka Agritech’s 3.61.

Mojo Score and Analyst Ratings

MarketsMOJO’s proprietary scoring system assigns Sharda Cropchem a Mojo Score of 81.0, upgrading its grade from Buy to Strong Buy as of 29 October 2025. This upgrade reflects improved fundamentals, robust earnings growth, and favourable valuation dynamics despite the shift to a fair valuation grade. The company’s market capitalisation grade remains at 3, indicating a mid-tier large-cap status that balances liquidity and growth potential.

Investment Implications

For investors, the transition from an attractive to a fair valuation grade signals a maturing phase in Sharda Cropchem’s market journey. While the stock is no longer a deep value play, its strong financial metrics, impressive returns, and reasonable multiples make it a compelling candidate for growth-oriented portfolios. The low PEG ratio suggests that earnings growth is not fully reflected in the current price, offering upside potential if the company continues to execute effectively.

However, investors should remain mindful of sector-specific risks, including regulatory changes, commodity price volatility, and global agricultural demand fluctuations. The modest dividend yield indicates that the company prioritises reinvestment over immediate income, aligning with its growth trajectory but potentially limiting appeal for income-focused investors.

Conclusion: Valuation Recalibration Reflects Growth Maturity

Sharda Cropchem Ltd’s valuation shift from attractive to fair is a natural progression given its strong share price appreciation and solid financial performance. While the company no longer trades at a deep discount, its valuation remains reasonable relative to peers, supported by high returns on capital and a very low PEG ratio. The stock’s exceptional market returns over one, three, five, and ten-year periods underscore its growth credentials and resilience in a competitive sector.

Investors seeking exposure to the pesticides and agrochemicals industry would do well to consider Sharda Cropchem as a balanced growth opportunity, combining solid fundamentals with a valuation that, while fair, still offers potential upside. The recent upgrade to a Strong Buy rating by MarketsMOJO further validates this stance, signalling confidence in the company’s future prospects.

As always, potential investors should weigh sector risks and individual portfolio objectives before committing capital, but Sharda Cropchem’s current profile suggests it remains a noteworthy contender in the agrochemical space.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →